β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Seth B. Coffelt, Anne Helene Køstner et al.|Cancer Immunology Research|2023Cited by 27
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerPhilip D. Dunne, Mark Lawler|Oncotarget|2018Cited by 11
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerPhilip D. Dunne, Mark Lawler|bioRxiv (Cold Spring Harbor Laboratory)|2017Cited by 1
Table S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Seth B. Coffelt, Anna Kilbey et al.|Unknown|2023Cited by 0
Figure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon CancerToshiyasu Suzuki, Seth B. Coffelt, Anna Kilbey et al.|Unknown|2023Cited by 0